CEO Interview

Developing Unique, Life Saving Medical Products

Odyssey Health Inc. (formerly Odyssey Group International, Inc.) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.

Odyssey’s novel pharmaceutical compound, PRV-002, is intended for the treatment of concussion. PRV-002 is a new chemical entity administered nasally with proven in-vivo efficacy and safety in concussion models. Pre-clinical results show significantly improved sensory motor function and significantly improved memory scores. The drug is currently in a Phase 1 human trial.

Beyond concussion, Odyssey envisions treating related brain injuries and neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and ALS, with other novel neurosteroids.

Odyssey’s medical devices in development include the CardioMap® and Save-a-Life Device®. The CardioMap® serves as a 30-second EKG machine with a cloud-based algorithm, which provides physicians a 3D map of a patient’s heart. This provides actionable information in real time. Save-A-Life® is a patented, handheld anti-choking device that creates a vacuum chamber in the mouth to dislodge obstructions. In the U.S., choking results in 100,000 annual ER visits and is the 4th leading cause of unintentional death. Save-A-Life® is easy to use by both adults and children and can be self-administered.

ODYY Device ODYY Device